Peter Sguigna, MD, assistant professor of neurology at UT Southwestern Medical Center in Dallas, Texas, spoke on emerging research, innovative biomarkers, and expanding targeted therapies for patients living with NMOSD.
Demyelinating & Neuroimmunologic Disorders
Constance V. Katsafanas, DO, director of the Neurology Residency Program at the Marcus Neuroscience Institute, highlighted the importance of individualized treatment strategies in multiple sclerosis.
The director of the Neurology Residency Program at the Marcus Neuroscience Institute detailed the importance of tailoring treatment to patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Benjamin Greenberg, MD, internationally recognized NMOSD expert, discussed the growing use of recently approved therapies, the importance of early diagnosis, and investigational approaches, including biomarker development and CAR-T therapy, for NMOSD Awareness Month.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis
2
Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM
3
Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action
4
FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis
5